The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke.

A leading cardiology doctor says this reinforces the importance of studying gender-specific health trends in research.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.In the 7MM, the 12-month total prevalent cases of migraine are expected to increase from 74,226,117 cases in ...

A history of migraine, with or without aura, was a significant risk factor for open-angle glaucoma onset among a cohort of ...

Women taking the beta blocker propranolol to ward off migraines have a lower risk of strokes caused by blood clots, according ...

Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment ...

particularly those who experience migraine without aura. This is an important discovery for those dealing with migraines." Mogos also noted that migraine disproportionately affects women from ...

For patients with migraine, the clinical benefits of propranolol, a beta-blocker medication, may extend beyond just migraine ...

Propranolol, a beta blocker medication used for treating high blood pressure and preventing migraines, may lower ischemic ...

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.